BioCentury
ARTICLE | Clinical News

CK-2127107: Phase II started

July 18, 2016 7:00 AM UTC

The partners began a double-blind, placebo-controlled, 2-way crossover, U.S. Phase II trial to evaluate 500 mg oral CK-107 twice daily for 14 days in about 40 patients. Astellas and Cytokinetics are d...